Cole E, Naimark D, Aprile M, Wade J, Cattran D, Pei Y, Fenton S, Robinette M, Zaltsman J, Bear R
Renal Transplantation Programme, University of Toronto, Ontario, Canada.
Clin Transplant. 1995 Aug;9(4):282-8.
To determine factors predictive of long-term graft function in patients treated prophylactically with an antilymphocyte antibody, 670 first cadaveric adult renal transplant procedures performed between 1985 and 1991 were reviewed. The actuarial 1- and 5-year patient survival in this group was 95% and 87% respectively, and graft survival was 84% and 70% respectively. The final analysis was based on a study group of 635 patients which excluded 28 patients who lost grafts to early technical failures and 8 patients who were not induced with an antilymphocyte preparation. Multivariate analysis showed that 5-year graft survival was lower in patients with delayed graft function (p = 0.0001), in those who had an acute rejection episode in the first 6 months post-transplant (p = 0.0001), recipients greater than 55 years of age at the time of transplant (p = 0.0001), in patients who were highly sensitized at the time of transplant (p = 0.0331) and, finally, in those who received a graft from an older donor (p = 0.044). The 209 patients with delayed graft function had a 16% lower long-term graft survival than 425 patients with early graft function (62% vs. 78% respectively at 5 years). One or more rejection episodes in the first 6 months post-transplant (329 patients) reduced long-term graft survival by 13% compared to those who did not have a rejection episode (67% vs. 80% respectively at 5 years).(ABSTRACT TRUNCATED AT 250 WORDS)
为确定接受抗淋巴细胞抗体预防性治疗患者长期移植肾功能的预测因素,我们回顾了1985年至1991年间进行的670例首次尸体供肾成人肾移植手术。该组患者1年和5年的实际生存率分别为95%和87%,移植肾生存率分别为84%和70%。最终分析基于635例患者的研究组,排除了28例因早期技术失败而移植肾失功的患者以及8例未接受抗淋巴细胞制剂诱导治疗的患者。多因素分析显示,移植肾功能延迟的患者5年移植肾生存率较低(p = 0.0001),移植后前6个月发生急性排斥反应的患者5年移植肾生存率较低(p = 0.0001),移植时年龄大于55岁的受者5年移植肾生存率较低(p = 0.0001),移植时高度致敏的患者5年移植肾生存率较低(p = 0.0331),最后,接受老年供者移植肾的患者5年移植肾生存率较低(p = 0.044)。209例移植肾功能延迟的患者长期移植肾生存率比425例移植肾功能早期恢复的患者低16%(5年时分别为62%和78%)。与未发生排斥反应的患者相比,移植后前6个月发生一次或多次排斥反应的329例患者长期移植肾生存率降低了13%(5年时分别为67%和80%)。(摘要截选至250词)